Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
December 2023
Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort
Arthritis Rheumatol. 2023; 75(12):2195–2206 DOI: 10.1002/art.42645
n this study, severe nonadherence to hydroxychloroquine (HCQ) was independently associated with the risk of SLE flare in the following year, early damage and 5-year mortality.
Keywords:
February 2023
Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling
Arthritis Care Res (Hoboken). 2023 doi: 10.1002/acr.25090.
First study to assess the long-term economic burden of neurologic and/or psychiatric (NP) lupus in an international, multi-ethnic inception cohort, concludes that patients with new/ongoing SLE or non-SLE NP events incurred higher direct and indirect costs.
Evaluating the Construct of Damage in Systemic Lupus Erythematosus
Arthritis Care Res (Hoboken). 2021 Dec 28. Epub ahead of print
Study identifies shifts in the paradigm of systemic lupus erythematosus (SLE) damage and develops a unifying conceptual framework to inform development of a revised SLE Damage Index (SDI).
Shifts in the concept of damage in SLE have occurred with new insights into disease manifestations, diagnostics, and therapy. Consequently, there is a need for a revised SDI, to incorporate additional factors that contribute to damage accrual.
Flares after Hydroxychloroquine Reduction or Discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ann Rheum Dis. 2021:annrheumdis-2021-221295. Epub ahead of print
Evidence suggests that hydroxychloroquine (HCQ) reduction/withdrawal may be safe in some stable patients, but in other settings it may be associated with disease flare. Almeida-Brasil, et al. sought to evaluate SLE flares following HCQ reduction or discontinuation versus HCQ maintenance. Their data suggest that maintaining HCQ was associated with a lower flare risk than reduction or discontinuation, even in patients with low disease activity or remission.